drugset / Trial / NCT03905902
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Phase 3
Withdrawn
SOTIO a.s.
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Multi-center, phase III trial of DCVAC/OvCa added to standard of care treatments for relapsed ovarian cancer. Patients will receive study treatment until all doses are administered, or other criteria are met.
Timeline
- Start
- 2021-08
- Primary completion
- 2021-08
- Completion
- 2021-08-16
Outcome
Outcome not reported
Stopped: “Company decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STAPULDENCEL | Vaccine | — | — |